163 related articles for article (PubMed ID: 35215901)
1. Hepatitis C Screening and Treatment Program in Hungarian Prisons in the Era of Direct Acting Antiviral Agents.
Werling K; Hunyady B; Makara M; Nemesi K; Horváth G; Schneider F; Enyedi J; Müller Z; Lesch M; Péterfi Z; Tóth T; Gács J; Fehér Z; Ujhelyi E; Molnár E; Nemes Nagy A
Viruses; 2022 Feb; 14(2):. PubMed ID: 35215901
[TBL] [Abstract][Full Text] [Related]
2. [Screening and treatment of hepatitis C virus in prisons: 10 years of experience].
Werling K; Makara M; Nemesi K; Horváth G; Schneider F; Bali I; Enyedi J; Jancsik V; Káfony A; Lesch M; Lombay B; Müller Z; Ozsvár Z; Patai Á; Péterfi Z; Pusztay M; Szabó O; Szlávik J; Tóth T; Varga M; Gács J; Újhelyi E; Nemes Nagy A
Orv Hetil; 2022 May; 163(22):871-878. PubMed ID: 35895613
[TBL] [Abstract][Full Text] [Related]
3. Brief Report: HCV Universal Test-and-Treat With Direct Acting Antivirals for Prisoners With or Without HIV: A Prison Health Care Workers-Led Model for HCV Microelimination in Thailand.
Supanan R; Han WM; Harnpariphan W; Ueaphongsukkit T; Ubolyam S; Sophonphan J; Tangkijvanich P; Thanprasertsuk S; Avihingsanon A;
J Acquir Immune Defic Syndr; 2021 Dec; 88(5):465-469. PubMed ID: 34757974
[TBL] [Abstract][Full Text] [Related]
4. Continuum of hepatitis C care cascade in prison and following release in the direct-acting antivirals era.
Hariri S; Sharafi H; Sheikh M; Merat S; Hashemi F; Azimian F; Tamadoni B; Ramazani R; Gouya MM; Abbasi B; Tashakorian M; Alasvand R; Alavian SM; Poustchi H; Malekzadeh R
Harm Reduct J; 2020 Oct; 17(1):80. PubMed ID: 33081794
[TBL] [Abstract][Full Text] [Related]
5. The effect of direct-acting antiviral regimens and telemedicine on the treatment of inmates with hepatitis C virus infection in Israeli prisons.
Richter V; Goldstein L; Cohen DL; Bermont A; Zelnik Yovel D; Madar M; Rabinovitch R; Shirin H; Broide E
Sci Prog; 2022; 105(2):368504221105173. PubMed ID: 35722762
[TBL] [Abstract][Full Text] [Related]
6. Impact of 5 years of hepatitis C testing and treatment in the North East of England prisons.
Johnson A; Shearer J; Thompson C; Jelley R; Aldridge J; Allsop C; Kerry J; Jones D; McCullough F; Miller C; Valappil M; Taha Y; Masson S; Jefferson T; Lawton C; Christensen L; McPherson S
J Viral Hepat; 2023 Dec; 30(12):914-921. PubMed ID: 37700492
[TBL] [Abstract][Full Text] [Related]
7. Hepatitis C virus serologic relapse after treatment with direct-acting antivirals is dependent on viral RNA levels in peripheral blood mononuclear cells and the grade of liver cirrhosis.
Abd Alla MDA; El Awady MK; Dawood RM; Elhawary MA; Al-Azhari SS; Galal AGM
Arch Virol; 2018 Oct; 163(10):2765-2774. PubMed ID: 29971486
[TBL] [Abstract][Full Text] [Related]
8. Hepatitis C virus infection in jail: Difficult-to-reach, not to-treat. Results of a point-of-care screening and treatment program.
Masarone M; Caruso R; Aglitti A; Izzo C; De Matteis G; Attianese MR; Pagano AM; Persico M
Dig Liver Dis; 2020 May; 52(5):541-546. PubMed ID: 32234417
[TBL] [Abstract][Full Text] [Related]
9. Outcomes of a nurse-led model of care for hepatitis C assessment and treatment with direct-acting antivirals in the custodial setting.
Overton K; Clegg J; Pekin F; Wood J; McGrath C; Lloyd A; Post JJ
Int J Drug Policy; 2019 Oct; 72():123-128. PubMed ID: 30967329
[TBL] [Abstract][Full Text] [Related]
10. Hepatitis virus (HCV) diagnosis and access to treatment in a UK cohort.
Adland E; Jesuthasan G; Downs L; Wharton V; Wilde G; McNaughton AL; Collier J; Barnes E; Klenerman P; Andersson M; Jeffery K; Matthews PC
BMC Infect Dis; 2018 Sep; 18(1):461. PubMed ID: 30217169
[TBL] [Abstract][Full Text] [Related]
11. Family Practitioner-Directed Hepatitis C Therapy With Direct-Acting Antivirals Achieves High-Sustained Virologic Response in Prison Population.
Mokkarala S; Johnson C; Sarkar S; Rudas RJ
J Correct Health Care; 2019 Apr; 25(2):134-142. PubMed ID: 30866706
[TBL] [Abstract][Full Text] [Related]
12. Hepatitis C screening, diagnosis, and cascade of care among people aged > 40 years in Brasilia, Brazil.
Carvalho-Louro DM; Soares EB; Trevizoli JE; Marra TMG; da Cunha ALR; Rodrigues MP; Carvalho-Furtado ACL; Dos Santos BTA; de Assis da Rocha Neves F
BMC Infect Dis; 2020 Feb; 20(1):114. PubMed ID: 32041537
[TBL] [Abstract][Full Text] [Related]
13. [Efficacy and safety of boceprevir based triple therapy in Hungarian patients with hepatitis C genotype 1 infection, advanced stage fibrosis and prior treatment failure].
Hunyady B; Abonyi M; Csefkó K; Gervain J; Haragh A; Horváth G; Jancsik V; Makkai E; Müller Z; Ribiczey P; Sipos B; Szabó O; Szalay F; Szentgyörgyi L; Tornai I; Újhelyi E; Varga M; Weisz G; Makara M
Orv Hetil; 2016 Aug; 157(34):1366-74. PubMed ID: 27546804
[TBL] [Abstract][Full Text] [Related]
14. Prevalence and correlates of HCV, HVB, and HIV infection among prison inmates and staff, Hungary.
Tresó B; Barcsay E; Tarján A; Horváth G; Dencs A; Hettmann A; Csépai MM; Gyori Z; Rusvai E; Takács M
J Urban Health; 2012 Feb; 89(1):108-16. PubMed ID: 22143408
[TBL] [Abstract][Full Text] [Related]
15. Outreach onsite treatment with a simplified pangenotypic direct-acting anti-viral regimen for hepatitis C virus micro-elimination in a prison.
Chen CT; Lu MY; Hsieh MH; Tsai PC; Hsieh TY; Yeh ML; Huang CI; Tsai YS; Ko YM; Lin CC; Chen KY; Wei YJ; Hsu PY; Hsu CT; Jang TY; Liu TW; Liang PC; Hsieh MY; Lin ZY; Huang CF; Huang JF; Dai CY; Chuang WL; Shih YL; Yu ML
World J Gastroenterol; 2022 Jan; 28(2):263-274. PubMed ID: 35110949
[TBL] [Abstract][Full Text] [Related]
16. Hepatitis C Virus Elimination Program among Prison Inmates, Israel.
Eisen L; Mor Z; Madar M; Rabinovitch R; Dadon Y; Sheffer R; Kaliner E; Goldstein L
Emerg Infect Dis; 2023 Nov; 29(11):2358-2361. PubMed ID: 37877627
[TBL] [Abstract][Full Text] [Related]
17. Combined treatment and prevention strategies for hepatitis C virus elimination in the prisons in New South Wales: a modelling study.
Bretaña NA; Gray RR; Cunningham EB; Betz-Stablein B; Ribeiro R; Graw F; Luciani F; Lloyd AR
Addiction; 2020 May; 115(5):901-913. PubMed ID: 31633853
[TBL] [Abstract][Full Text] [Related]
18. Microenvironment Eradication of Hepatitis C: A Novel Treatment Paradigm.
Cuadrado A; Llerena S; Cobo C; Pallás JR; Mateo M; Cabezas J; Fortea JI; Alvarez S; Pellón R; Crespo J; Echevarría S; Ayesa R; Setién E; Lopez-Hoyos M; Crespo-Facorro B; Agüero J; Chueca N; Garcia F; Calleja JL; Crespo J
Am J Gastroenterol; 2018 Nov; 113(11):1639-1648. PubMed ID: 29946175
[TBL] [Abstract][Full Text] [Related]
19. Psychosocial Factors and the Care Cascade for Hepatitis C Treatment Colocated at a Syringe Service Program.
Winetsky D; Burack D; Antoniou P; Garcia B; Gordon P; Scherer M
J Infect Dis; 2020 Sep; 222(Suppl 5):S392-S400. PubMed ID: 32877544
[TBL] [Abstract][Full Text] [Related]
20. HCV testing and treatment initiation in an Italian prison setting: A step-by-step model to micro-eliminate hepatitis C.
Fiore V; De Matteis G; Ranieri R; Saderi L; Pontali E; Muredda A; Ialungo AM; Caruso R; Madeddu G; Sotgiu G; Babudieri S
Int J Drug Policy; 2021 Apr; 90():103055. PubMed ID: 33310637
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
